Login to Your Account



In The Clinic NEWS

Alcobra Ltd. is yanking development of MDX in the lead indication of ADHD in adults after the phase III registration trial, MEASURE, failed to demonstrate a statistically significant difference from placebo in change from baseline of the investigator rating of Conners' Adult ADHD Rating Scales, the primary endpoint.

Concert Pharmaceuticals Inc. said in order to support dose selection for a future phase III trial of CTP-656 in CF, the FDA will require its ongoing phase II trial to institute a washout period during which Kalydeco treatment would be withheld.

Curevac AG's mRNA-based prostate cancer vaccine CV9104, long its lead candidate, failed to meet the primary endpoint of improving overall survival during a phase IIb trial.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: